Abstract
EGFR-directed therapy in lung cancer is here to stay, with new drugs targeting T790M-mediated resistance coming quickly and the field continuing to advance. With greater access to sophisticated tools for interrogating both the somatic and germline genome, and with widespread acceptance of the scientific and clinical value of obtaining serial repeated biopsies from patients with oncogene-addicted tumors, the field is poised to answer more nuanced questions.